Loading...

Fate Therapeutics, Inc.

FATE•NASDAQ
Healthcare
Biotechnology
$2.43
$0.14(6.11%)
U.S. Market opens in 3h 4m

Fate Therapeutics, Inc. (FATE) Stock Overview

Explore Fate Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap282.5M
P/E Ratio-2.09
EPS (TTM)$-1.15
ROE-0.55%
Fundamental Analysis

AI Price Forecasts

1 Month$1.83
3 Months$0.89
1 Year Target$0.82

FATE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Fate Therapeutics, Inc. (FATE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 83.15, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.82.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.09 and a market capitalization of 282.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
6.11%
5-Day Change
94.40%
1-Month Change
111.30%
3-Month Change
113.16%
6-Month Change
127.10%
Year-to-Date (YTD) Change
147.30%
1-Year Change
143.00%
3-Year Change
-55.41%
5-Year Change
-96.82%
All-Time (Max) Change
-63.29%

Contact Information

https://www.fatetherapeutics.com
858 875 1800
12278 Scripps Summit Drive, San Diego, CA, 92131

Company Facts

181 Employees
IPO DateOct 1, 2013
CountryUS
Actively Trading

Frequently Asked Questions